<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34755316</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-0100</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>75</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Endocrine</Title>
          <ISOAbbreviation>Endocrine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Malignancy risk in indeterminate thyroid nodules with Hürthle cells: role of autoimmune thyroiditis.</ArticleTitle>
        <Pagination>
          <StartPage>823</StartPage>
          <EndPage>828</EndPage>
          <MedlinePgn>823-828</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12020-021-02932-6</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Hürthle cells are modified follicular thyroid cells, whose development and proliferation have been related to different stimuli inducing cellular stress. Most thyroid aspirates containing Hürthle cells are classified as indeterminate, although the specific risk of malignancy for this subtype of atypia remains unclear. The aim of our study was to assess if the presence of Hürthle cells in indeterminate thyroid nodules correlates with the risk of malignancy. We further evaluated if this risk can be modified by the presence of an underlying Hashimoto's thyroiditis.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We retrospectively analyzed all indeterminate thyroid nodules that were surgically treated at our institution between January 2010 and March 2019. For each nodule, we inferred the presence of Hürthle cells in the cytological report. Cytological findings were then correlated with histological reports.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">354 indeterminate thyroid nodules were included in the study. The rate of malignancy resulted significantly lower in nodules exhibiting Hürthle cells compared to those negative for this cellular pattern (11.4% vs 22.5%, p = 0.01). Although there was no difference in the rate of malignancy in the whole population according to the presence or absence of Hashimoto's thyroiditis (21.5 vs 18.5%, p = 0.63), the significantly lower prevalence of malignant lesions in nodules with Hürthle cells was confirmed only in the presence of a histologically documented Hashimoto's thyroiditis (6.2% vs 32%, p = 0.005).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The finding of Hürthle cells in indeterminate thyroid nodules is associated with a low risk of malignancy in patients with an underlying Hashimoto's thyroiditis. The clinical management of these lesions may therefore be more conservative.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Perticone</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-0010-0998</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy. perticone.francesca@hsr.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maggiore</LastName>
            <ForeName>Riccardo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Surgery Unit, Department of Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mari</LastName>
            <ForeName>Gilberto</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Surgery Unit, Department of Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frara</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baldassarre</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doglioni</LastName>
            <ForeName>Claudio</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lena</LastName>
            <ForeName>Marco Schiavo</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosati</LastName>
            <ForeName>Riccardo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Surgery Unit, Department of Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lanzi</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giustina</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocrine</MedlineTA>
        <NlmUniqueID>9434444</NlmUniqueID>
        <ISSNLinking>1355-008X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D050031" MajorTopicYN="Y">Hashimoto Disease</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016606" MajorTopicYN="Y">Thyroid Nodule</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013967" MajorTopicYN="Y">Thyroiditis, Autoimmune</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Hürthle cells</Keyword>
        <Keyword MajorTopicYN="N">Indeterminate thyroid nodules</Keyword>
        <Keyword MajorTopicYN="N">Malignancy risk</Keyword>
        <Keyword MajorTopicYN="N">Thyroid cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34755316</ArticleId>
        <ArticleId IdType="doi">10.1007/s12020-021-02932-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s12020-021-02932-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Trimboli, P., Crescenzi, A., Giovanella, L.: Performance of Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) in discriminating indeterminate lesions at low and high risk of malignancy. A systematic review and meta-analysis. Endocrine. (2018). https://doi.org/10.1007/s12020-017-1382-6</Citation>
        </Reference>
        <Reference>
          <Citation>Cibas, E.S., Ali, S.Z.: The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. (2017). https://doi.org/10.1089/thy.2017.0500</Citation>
        </Reference>
        <Reference>
          <Citation>Nardi, F., Basolo, F., Crescenzi, A., Fadda, G., Frasoldati, A., Orlandi, F., Palombini, L., Papini, E., Zini, M., Pontecorvi, A., Vitti, P.: Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Investig. (2014). https://doi.org/10.1007/s40618-014-0062-0</Citation>
        </Reference>
        <Reference>
          <Citation>Straccia, P., Santoro, A., Rossi, E.D., Brunelli, C., Mosseri, C., Musarra, T., Pontecorvi, A., Lombardi, C.P., Fadda, G.: Incidence, malignancy rates of diagnoses and cyto-histological correlations in the new Italian Reporting System for Thyroid Cytology: An institutional experience. Cytopathology (2017). https://doi.org/10.1111/cyt.12455</Citation>
        </Reference>
        <Reference>
          <Citation>Renshaw, A.A.: Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol. (2010). https://doi.org/10.1002/cncy.20091</Citation>
        </Reference>
        <Reference>
          <Citation>T.S. Greaves, M. Olvera, B.D. Florentine, A.S. Raza, C.J. Cobb, D.D. Tsao-Wei, S. Groshen, P. Singer, J. Lopresti, S.E. Martin, Follicular lesions of thyroid: A 5-year fine-needle aspiration experience. Cancer 90, 335–341 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(20001225)90:6&lt;335::AID-CNCR3&gt;3.0.CO;2-L</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sclabas, G., Staerkel, G., Shapiro, S., Fornage, B., Sherman, S., Vassillopoulou-Sellin, R., Lee, J., Evans, D.: Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am. J. Surg. (2003). https://doi.org/10.1016/j.amjsurg.2003.08.015</Citation>
        </Reference>
        <Reference>
          <Citation>Sobrinho-Simões, M., Máximo, V., Vieira de Castro, I., Fonseca, E., Soares, P., Garcia-Rostan, G., Cardoso de Oliveira, M.: Hürthle (oncocytic) cell tumors of thyroid: Etiopathogenesis, diagnosis and clinical significance. Int. J. Surg. Pathol. (2005). https://doi.org/10.1177/106689690501300104</Citation>
        </Reference>
        <Reference>
          <Citation>Pu, R., Yang, J., Wasserman, P., Bhuiya, T., Griffith, K., Michael, C.: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn. Cytopathol. (2006). https://doi.org/10.1002/dc.20440</Citation>
        </Reference>
        <Reference>
          <Citation>Cannon, J.: The significance of Hurthle cells in thyroid disease. Oncologist. (2011). https://doi.org/10.1634/theoncologist.2010-0253</Citation>
        </Reference>
        <Reference>
          <Citation>Auger, M.: Hürthle cells in fine-needle aspirates of the thyroid: a review of their diagnostic criteria and significance. Cancer Cytopathol. (2014). https://doi.org/10.1002/cncy.21391</Citation>
        </Reference>
        <Reference>
          <Citation>Sparano, C., Parenti, G., Cilotti, A., Bencini, L., Calistri, M., Mannucci, E., Biagini, C., Vezzosi, V., Mannelli, M., Forti, G., Pertrone, L.: Clinical impact of the new SIAPEC-IAP classification on the indeterminate category of thyroid nodules. J. Endocrinol. Invest. (2019). https://doi.org/10.1007/s40618-018-0871-7</Citation>
        </Reference>
        <Reference>
          <Citation>Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., Sawka, A.M., Schlumberger, M., Schuff, K.G., Sherman, S.I., Sosa, J.A., Steward, D.L., Tuttle R.M., Wartofsky, L.: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016). https://doi.org/10.1089/thy.2015.0020</Citation>
        </Reference>
        <Reference>
          <Citation>Durante, C., Grani, G., Lamartina, L., Filetti, S., Mandel, S.J., Cooper, D.S. The diagnosis and management of thyroid nodules: a review. JAMA. (2018). https://doi.org/10.1001/jama.2018.0898</Citation>
        </Reference>
        <Reference>
          <Citation>Lim, H., Devesa, S.S., Sosa, J.A., Check, D., Kitahara, C.M. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. (2017). https://doi.org/10.1001/jama.2017.2719</Citation>
        </Reference>
        <Reference>
          <Citation>Krauss, E., Mahon, M., Fede, J., Zhang, L.: Application of the Bethesda classification for thyroid fine-needle aspiration institutional experience and meta-analysis. Arch. Pathol. Lab. Med. (2016). https://doi.org/10.5858/arpa.2015-0154-SA</Citation>
        </Reference>
        <Reference>
          <Citation>Giorgadze, T., Rossi, E.D., Fadda, G., Gupta, P.K., Livolsi, V.A., Baloch, Z.: Does the fine-needle aspiration diagnosis of “Hürthle-cell neoplasm/follicular neoplasm with oncocytic features” denote increased risk of malignancy? Diagn. Cytopathol. (2004). https://doi.org/10.1002/dc.20132</Citation>
        </Reference>
        <Reference>
          <Citation>Ren, Y., Kyriazidis, N., Faquin, W.C., Soylu, S., Kamani, D., Saade, R., Torchia, N., Lubitz, C., Davies, L., Stathatos, N., Stephen A.E., Randolph, G.W.: The Presence of Hurthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates. Thyroid. (2020). https://doi.org/10.1089/thy.2019.0190</Citation>
        </Reference>
        <Reference>
          <Citation>Ruggeri, R.M., Campennì, A., Giuffrida, G., Casciaro, M., Barbalace, M.C., Hrelia, S., Trimarchi, F., Cannavò, S., Gangemi, S. Oxidative stress as a key feature of autoimmune thyroiditis: an update. Minerva Endocrinol. (2020). https://doi.org/10.23736/S0391-1977.20.03268-X</Citation>
        </Reference>
        <Reference>
          <Citation>Roh, M.H., Jo, V.Y., Stelow, E.B., Faquin, W.C., Zou, K.H., Alexander, E.K., Larsen, P.R., Marqusee, E., Benson, C.B., Frates, M.C., Gawande, A., Moore Jr F.D., Cibas, E.S.: The predictive value of the fine-needle aspiration diagnosis “suspicious for a follicular neoplasm, Hurthle cell type” in patients with Hashimoto thyroiditis. Am. J. Clin. Pathol. (2011) https://doi.org/10.1309/AJCP0RW2WMDUAKGK</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
